1. Introduction {#sec1}
===============

Malaria continues to be a significant global health burden causing over 228 million clinical cases and 405 000 fatalities annually ([@bib40]). The World Health Organisation African Region, accounts for over 90% of all of these cases ([@bib40]). The perpetual challenge posed by the emergence of drug-resistant *Plasmodium falciparum* strains hampers the fight against malaria and underscores the need to discover and develop new antimalarial drugs ([@bib23]; [@bib31]). To achieve the goal of malaria elimination, these new drug entities ought to be active against multiple life cycle stages of *Plasmodium* parasites including the proliferative asexual forms that cause pathology and also should be able to interrupt parasite transmission, both human to mosquito (targeting sexual gametocytes) and mosquito to human (targeting hepatic asexual parasites) ([@bib8]).

Naphthylisoquinoline (NIQ) alkaloids are secondary metabolites isolated from lianas that belong to the tropical plant families Ancistrocladaceae and Dioncophyllaceae exclusively. All representatives of this class of natural products are built up from a naphthalene moiety and an isoquinoline subunit, which are linked via a biaryl axis. This leads to a broad structural diversity of the compounds, among them *C*,*C*- and *N*,*C-*coupled NIQs, but also dimeric representatives ([@bib4]; [@bib6]; [@bib17]; [@bib25]; [@bib27]). NIQs display outstanding anti-infective activities against parasitic pathogens causing diseases such as leishmaniasis ([@bib4]; [@bib32]) and trypanosomiasis ([@bib3]). Moreover, these agents have been shown to be potent antiplasmodial compounds with *in vitro* and even *in vivo* activity against the exo-erythrocytic (hepatic) stages of *Plasmodium* ([@bib19], [@bib20]) and both chloroquine-sensitive and -resistant intra-erythrocytic asexual stage parasites ([@bib4], [@bib7]; [@bib18], [@bib21], [@bib19], [@bib20]). Dioncophylline A (**1**), dioncophylline C (**2a**), and jozimine A~2~ (**3a**) are promising candidates for more in-depth investigations as possible lead compounds for the development of new antimalarial agents ([Fig. 1](#fig1){ref-type="fig"}). Dioncophylline A (**1**) is the most potent NIQ against exo-erythrocytic stages *in vitro* ([@bib19], [@bib20]) whilst dioncophylline C (**2a**) is efficient both *in vitro* and *in vivo* against the murine *P. berghei* parasite, where parasitaemia was decreased (99.6%) after a single oral dose and a radical cure was achieved after a 4-day Peter\'s suppressive test ([@bib22]). The dimeric alkaloid jozimine A~2~ (**3a**) selectively kills asexual *P. falciparum in vitro* (IC~50~ of 0.0014 μM) with mammalian cells unaffected even at \>11 000-fold increased doses ([@bib7]).Fig. 1Structures of dioncophyllines A (**1**) and C (**2a**) and of the dimeric alkaloid jozimine A~2~ (**3a**).Fig. 1

Despite their outstanding antiplasmodial activities, NIQs are usually difficult to isolate, also due to the rare plant resources. Moreover, in view of their special chirality, and they are complex to synthesise, which leads to limited accessible quantities of these compounds. To mitigate this, quantitative structure-activity relationship (QSAR) guided studies were used to synthesise simplified and easily accessible novel antiplasmodial NIQ analogues ([@bib2]). To advance NIQs in a hit-to-lead strategy, we report here the further, mechanistic validation of selected NIQs as well as their synthetic analogues, with activity against both asexual (Target Candidate Profile, TCP-1) and gametocyte stages (TCP-5) of *P. falciparum*. Additionally, we describe the effect of a selection of these natural products and their analogues on β-haematin formation, their solubility and microsomal stability.

2. Material and methods {#sec2}
=======================

2.1. Selection of compounds {#sec2.1}
---------------------------

We selected prominent representatives of the different NIQ subclasses based on previously described antiplasmodial activities: dioncophylline A (**1**), dioncophylline C (**2a**), and jozimine A~2~ (**3a**), and a series of related substances ([Fig. 2](#fig2){ref-type="fig"}). While the 7,1′-coupled monomeric *C*,*C*-coupled alkaloids habropetaline A (**4**) and dioncopeltine A (**5**) are closely related to dioncophylline A (**1**), 5-*epi*-dioncophylline C (**2b**) and its likewise 5,1′-coupled regioisomer **6** are derivatives of dioncophylline C (**2a**). Compounds **2b** and **6** were obtained by total synthesis using a Suzuki-Miyaura coupling approach, as described in detail in the Supplementary Information. As a representative of *N*,*C*-coupled NIQs we included ancistrocladinium A (**7**) into our investigations. Furthermore, four dimeric *C*,*C*-coupled analogues were studied more closely, namely ealapasamine C (**8**) from the Central African liana *Ancistrocladus ealaensis*, the synthetic 8,8″-*O*,*O*-dimethyl analogue **9** of michellamine A, jozibrevine C (**3b**), and jozilebomine A (**10**) from *A. ileboensis*. Two of these compounds, **8** and **9**, are 6′,6″-coupled dimers, consisting of either two 5,8′-linked halves as in the case of **9** or a 5,8′- and a 7,8′-coupled naphthylisoquinoline portion as in the case of the 'mixed' dimer **8**. In contrast to **3b** and **10**, their central axis is not an additional element of chirality but can rotate freely. The 3′,3″-coupled jozibrevine C (**3b**) and the 3′,6″-linked jozilebomine A (**10**) are characterised by the presence of even three consecutive chiral biaryl axes. All these molecules are genuine natural products, except for **2b**, **6**, and **9**, which have not been isolated from plant material yet but were synthesised as derivatives closely related to their lead structures dioncophylline C (**2a**) for **2b** and **6** and, akin to the michellamines, for the synthetic 6′,6″-coupled dimer **9**.Fig. 2The investigated natural and synthetic monomeric *C*,*C*- and *N*,*C*-coupled, and dimeric NIQ alkaloids.Fig. 2

Furthermore, we investigated the simplified analogues **11**--**28**, as structurally derived from NIQs ([Fig. 3](#fig3){ref-type="fig"}). Their molecular design was based on QSAR studies and they had previously been shown to exert antiplasmodial activities ([@bib2]).Fig. 3Structurally simplified unnatural analogues of NIQs.Fig. 3

2.2. In vitro continuous culture of intra-erythrocytic asexual P. falciparum parasites and gametocytogenesis induction {#sec2.2}
----------------------------------------------------------------------------------------------------------------------

*In vitro* culturing of intra-erythrocytic *P. falciparum* parasites and volunteer blood donation for human erythrocytes holds ethics approval from the University of Pretoria Faculty of Natural and Agricultural Sciences Ethics Committee (EC120821-077). *P. falciparum* parasite strains and clinical isolates ([@bib37]) were cultured to allow intra-erythrocytic asexual development in complete RPMI 1640 culture medium (supplemented with 25 mM HEPES, 20 mM D-glucose, 200 μM hypoxanthine, 0.2% sodium bicarbonate, 24 μg/ml gentamicin, and 0.5% AlbuMAX II) at 37 °C in human erythrocytes (O^+^) under hypoxic conditions (90% N~2~, 5% O~2~, and 5% CO~2~) ([@bib38]). Parasites were synchronised to a \>95% ring-stage population using D-sorbitol (5% w/v) ([@bib38]).

Gametocytogenesis was induced from synchronised asexual *P. falciparum* parasites of the transgenic luciferase-expressing strain NF54^-*Pf*s16-GFP-Luc^ (kind gift from D. A. Fidock, Columbia University, USA) and cultured as previously reported ([@bib33]).

2.3. In vitro assessment of activity against intra-erythrocytic asexual P. falciparum parasites {#sec2.3}
-----------------------------------------------------------------------------------------------

*In vitro* activity against asexual *P. falciparum* parasites was assessed using SYBR Green I fluorescence ([@bib38]). All compounds were assessed for auto-fluorescence ([Supplementary Information Table S1](#appsec1){ref-type="sec"}). Compounds were serially diluted (two-fold) in sterile 96-well plates (100 μl/well) followed by seeding with 100 μl/well of ring-stage *P. falciparum* parasites suspension (1% parasitaemia, 1% haematocrit), with a 96 h drug pressure at 37 °C. Chloroquine served as a positive control reference drug for inhibition of asexual parasites proliferation. Dose-response curves were obtained with GraphPad Prism (v6), from which half-maximal inhibitory concentration (IC~50~) values were deduced. Unless stated otherwise, assays were performed in technical triplicate for ≥2 biological repeats. Additionally, the IC~50~ value for jozimine A~2~ (**3a**) was confirmed with a parasite lactate dehydrogenase (pLDH) assay, as described elsewhere ([@bib28]).

2.4. In vitro cytotoxicity assessment {#sec2.4}
-------------------------------------

The lactate dehydrogenase (LDH) leakage assay was used to examine the *in vitro* cytotoxicity of NIQs and their analogues against cells of a human hepatocellular liver carcinoma cell line (HepG2), seeded at 20000 cells/well ([@bib11]). The cytotoxic natural product emetine and the antimalarial drug chloroquine served as references with assay set up and readout as described earlier ([@bib11]). Assays were performed in duplicate technical repeats for ≥2 biological repeats. Sigmoidal dose-response curves were plotted using GraphPad Prism (v6), from which the half-maximal effective concentration (EC~50~) values were determined.

2.5. β-Haematin inhibition assay {#sec2.5}
--------------------------------

Based on a method described earlier ([@bib9]; [@bib35]), the detergent mediated assay for β-haematin inhibition was performed using 96-well plates. The pyridine-ferrochrome method developed in the literature was used to measure unreacted haematin ([@bib29]). The UV-vis absorbances were monitored at 405 nm on a Thermo Scientific Multiskan GO plate reader (Thermo Scientific, Waltham, MA, USA). Data are from two independent repeats, each performed in technical duplicates. To calculate the IC~50~ values of each compound, sigmoidal dose-response curves were plotted using GraphPad Prism on means ± SD. (v6).

2.6. In vitro assessment of gametocytocidal activity and inhibition of male gamete exflagellation {#sec2.6}
-------------------------------------------------------------------------------------------------

Early- (\>85% stage II/III) and late-stage gametocyte (\>85% stage IV/V) assays (full dose-response investigations for two independent biological repeats, in technical triplicates) were performed as previously reported ([@bib33]) with a luciferase reporter assay after 48 h drug pressure. To investigate for inhibition of male gamete formation, mature gametocytes (\>95% stage V) were placed under 48 h drug pressure (single point screen at 2 μM for two independent biological repeat experiments) and then the exflagellation inhibition assay (EIA) was performed on gametes in a carry-over drug pressure format as described elsewhere ([@bib12]). Methylene blue served as a reference compound for inhibition for both *in vitro* gametocyte viability tests and for EIAs.

2.7. Solubility and metabolic stability of NIQ alkaloids and their analogues {#sec2.7}
----------------------------------------------------------------------------

Solubility of the compounds at pH 6.5 was assessed using an adapted miniaturised shake-flask method in 96-well plate format ([@bib1]; [@bib26]). Briefly, 4 μl of a 10 mM stock in 100% DMSO were added to a 96-well plate and evaporated using a GeneVac system. Phosphate-buffered saline (PBS) (pH 6.5) was added to the wells and the plate was incubated for 24 h at 25 °C with shaking. At the end of this incubation, the samples were centrifuged at 3500 *g* for 15 min and then transferred to an analysis plate. A calibration curve for each sample between 10 and 220 μM in DMSO was prepared and included in the analysis plate. Analysis was then performed by HPLC-DAD and solubility of each sample determined from the corresponding calibration curve.

The metabolic stability was investigated using a single-point assay ([@bib15]) optimised for phase I metabolic reactions. NIQ alkaloids and their analogues were incubated at 1 μM in human (mixed gender, Xenotech), rat (male rats IGS, Xenotech), and mouse (male mice CD1, Xenotech) liver microsomes (0.4 mg/ml) for 30 min at 37 °C. Reactions were quenched by adding ice-cold acetonitrile containing internal standard. The samples were then centrifuged and analysed by LC-MS/MS for the disappearance of parent compound. Intrinsic clearance was determined using standard equations ([@bib15]; [@bib30]).

3. Results {#sec3}
==========

3.1. Antiplasmodial activity of NIQs and their synthetic analogues {#sec3.1}
------------------------------------------------------------------

The *in vitro* activities of NIQs and their synthetic analogues were first assessed against drug-sensitive intra-erythrocytic asexual *P. falciparum* (NF54 strain) parasites using an SYBR Green I fluorescence assay ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table S1](#appsec1){ref-type="sec"}). Additionally, all compounds with sub-micromolar activity against NF54 were screened primarily against the multidrug-resistant W2 strain and further against a panel of seven drug-resistant strains and clinical isolates of African origin ([Supplementary Information Tables S2 and S3](#appsec1){ref-type="sec"}).Table 1Antiplasmodial and cytotoxic activity of NIQs and their synthetic analogues.Table 1CompoundInhibition of parasite proliferationCytotoxicityIC~50~ (μM)[a](#tbl1fna){ref-type="table-fn"}EC~50~ (μM)[a](#tbl1fna){ref-type="table-fn"}NF54W2RI[b](#tbl1fnb){ref-type="table-fn"}HepG2SI[c](#tbl1fnc){ref-type="table-fn"}Chloroquine0.013 ± 0.0010.382 ± 0.0929.537.0 ± 4.52855.4  **Monomeric NIQs**Dioncopeltine A (**5**)0.008 ± 0.0020.304 ± 0.0638.139.0 ± 13.14890.8Habropetaline A (**4**)0.015 ± 0.0020.084 ± 0.035.445.5 ± 12.12922.9Dioncophylline C (**2a**)0.038 ± 0.00020.112 ± 0.012.921.2 ± 4.0552.6Analogue **2b**[d](#tbl1fnd){ref-type="table-fn"}0.234 ± 0.0230.556 ± 0.112.4\>50\>50Analogue **6**[d](#tbl1fnd){ref-type="table-fn"}0.042 ± 0.0030.138 ± 0.023.325.0 ± 11.6602.4  **Dimeric NIQs**Jozimine A~2~ (**3a**)0.151 ± 0.0170.243 ± 0.091.64.1 ± 1.227.4Jozibrevine C (**3b**)0.265 ± 0.011NDNDNDNDJozilebomine A (**10**)0.167 ± 0.032NDNDNDNDEalapasamine C (**8**)0.063 ± 0.010.134 ± 0.0042.113.1 ± 3.5208.6Dimer **9**0.088 ± 0.0030.184 ± 0.062.130.5 ± 9.0347.1  **Simplified NIQs**[e](#tbl1fne){ref-type="table-fn"}Compound **12**0.990 ± 0.1050.962 ± 0.271.0\>50\>50Compound **18**0.740 ± 0.1290.866 ± 0.371.2\>50\>50Compound **22**0.715 ± 0.0840.238 ± 0.070.3\>50\>50Compound **23**0.517 ± 0.0180.285 ± 0.030.6\>50\>50Compound **27**0.576 ± 0.0270.796 ± 0.381.432.3 ± 5.656.0[^3][^4][^5][^6][^7][^8]

Among the 30 compounds evaluated, 15 exhibited sub-micromolar potency across all strains and clinical isolates ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table S1](#appsec1){ref-type="sec"}). Although dioncopeltine A (**5**) was the most potent NIQ against the NF54 strain (IC~50~ = 0.008 μM), it showed diminished potency against the multidrug-resistant W2 strain (IC~50~ = 0.304 μM; Resistance Index (RI) = 38.1). Interestingly, habropetaline A (**4**) (NF54 IC~50~ = 0.015 μM), which structurally differs from dioncopeltine A (**5**) only at the 5′-carbon, by having a methoxy instead of a hydroxy substituent in the naphthalene portion ([Fig. 2](#fig2){ref-type="fig"}), retained an acceptable RI of 5.4 against the W2 strain. Dioncophylline C (**2a**) (IC~50~ = 0.038 μM) was equipotent (against the NF54 strain) to its closely related derivative **6** (IC~50~ = 0.042 μM), which differed from **2a** by its opposite methoxy-hydroxy pattern in the naphthalene portion and by the configuration at the biaryl axis. However, both compounds had an approximately 5-fold difference in potency compared to **2b** (IC~50~ = 0.234 μM), the actual atropo-diastereomer of **2a**.

Regarding the dimeric compounds jozimine A~2~ (**3a**), its atropisomer, jozibrevine C (**3b**), as well as its regioisomer jozilebomine A (**10**), comparable values were obtained against the NF54 strain, with IC~50~ of 0.151 μM (IC~50~ = 0.178 μM, measured by using the pLDH assay), 0.167 μM and 0.265 μM, respectively, while ealapasamine C (**8**) and the michellamine-type dimer **9** scored even better. Similar results were observed in terms of their activity against the drug-resistant strains.

In agreement with the fact that the simplified analogues were structurally quite different from one another, their IC~50~ values varied to a high degree, ranging from 0.517 μM to 25.4 μM against the NF54 strain with three synthetic analogues (phenylisoquinoline **12** and the naphthyldihydroisoquinolines **22** and **23**), showing no *in vitro* cross-resistance with chloroquine ([Table 1](#tbl1){ref-type="table"} and [Supplementary Information Table S2](#appsec1){ref-type="sec"}). Some structural modifications were observed to either enhance or diminish the potency of synthetic analogues ([Supplementary Information Fig. S1](#appsec1){ref-type="sec"}). For instance, comparing the activities of the naphthyldihydroisoquinolines **19** with **20** and **22** with **24** ([Fig. 3](#fig3){ref-type="fig"}) showed that the substitution of a hydroxy function, as in **20** (IC~50~ = 1.63 μM) and **22** (IC~50~ = 0.715 μM), with a methoxy group, as in **19** (IC~50~ = 14.5) and **24** (IC~50~ = 6.09 μM), was accompanied by a loss in activity (\>8.5-fold variation in IC~50~ values). The methyl substituent in *para* position to the biaryl axis of **12** (IC~50~ = 0.99 μM) led to a \> 2-fold decrease in IC~50~ value compared to compounds in which substituents were either a hydrogen (as in **11**; IC~50~ = 5.09 μM), a trifluoromethyl group (as in **14**; IC~50~ = 4 μM) or a chlorine substituent (as for **16**; IC~50~ = 21.9 μM). Placement of a chlorine substituent in either the *para* (as for **16**) or the *meta* (as for **17**; IC~50~ = 1.93 μM) position resulted in significantly different potency levels (\>10-fold difference in IC~50~ values).

All compounds with sub-micromolar activity against asexual *P. falciparum* parasites exhibited minimal to no cytotoxicity against HepG2 cells (selectivity indices (SI) \> 10) with five of the structurally simplified analogues inactive even at 50 μM ([Table 1](#tbl1){ref-type="table"}).

3.2. Mechanistic studies {#sec3.2}
------------------------

Previous investigations wherein dioncophylline C (**2a**) had been shown to form a complex with haem using model studies ([@bib41]), had led to the hypothesis that inhibition of haemozoin formation might be responsible for part of its activity. To investigate this assumption, inhibition of β-haematin formation (synthetic haemozoin) was examined for dioncophylline C (**2a**) and its regioisomer **6**, which should also hit the same target as **2a**, as assumed based on its structural similarity and its activity profile against intra-erythrocytic asexual parasites. Indeed, both compounds (IC~50~ = 19.9 ± 3.1 μM for **2a** and 46.6 ± 4.7 μM for **6**) inhibited β-haematin formation with a potency that was quite similar to that of the reference compound used in the assay, chloroquine (IC~50~ = 13.9 ± 1.09 μM). In view of the cross-resistance of dioncopeltine A (**5**) to chloroquine, we furthermore hypothesised that it could also inhibit β-haematin formation, however **5** exhibited an IC~**5**0~ value of 134.1 ± 2.4 μM, i.e. above the cut-off threshold of IC~50~ \< 100 μM, which excluded haemozoin formation as its target.

3.3. Inhibition of viability of gametocyte stages and EIAs {#sec3.3}
----------------------------------------------------------

Driven by the goal to identify dual-active NIQs and synthetic analogues, we assessed the transmission-blocking activity of the 15 intra-erythrocytic asexual stage potent compounds by screening them *in vitro* against early- (\>85% stage II/III) and late-stage (\>85% stage IV/V) *P. falciparum* gametocytes ([Table 1](#tbl1){ref-type="table"}). Interestingly, of the 15 compounds examined, only the large-sized dimeric compounds jozimine A~2~ (**3a**), jozibrevine C (**3b**), ealapasamine C (**8**), dimer **9**, and jozilebomine A (**10**), consistently showed \>70% inhibition of viability of both gametocyte stages at 5 μM ([Fig. 4](#fig4){ref-type="fig"}a), with **3a**, **8**, and **9** displaying appreciable sub-micromolar *in vitro* gametocytocidal activities against both gametocyte stages ([Fig. 4](#fig4){ref-type="fig"}b). Among the NIQ dimers, jozimine A~2~ (**3a**) was the most active gametocytocidal compound with an IC~50~ value of 0.3--0.5 μM ([Fig. 4](#fig4){ref-type="fig"}b).Fig. 4*In vitro* gametocytocidal and gametocidal activity of NIQs and their synthetic analogues. The luciferase reporter line NF54^-*Pf*s16-GFP-Luc^ was used to assess *in vitro* early- (\>85% stage II/III) and late-stage (\>85% stage IV/V) gametocytocidal activity (a) single-point screen (5 μM, n = 1, gametocytaemia of 2% at final haematocrit of 1%) and (b) full dose-response (n = 2, mean ± SEM, \*n = 1, gametocytaemia of 2% at final haematocrit of 1%) investigations of compounds for 48 h incubation period and single-point screen (2 μM) EIA, n = 2, mean ± SEM. Methylene blue served as a reference compound inhibiting \>90% *in vitro* gametocyte (both early and late stages) viability at 5 μM. ND, not determined.Fig. 4

To examine if the observed inhibition of gametocyte viability was due to a blocking of male gamete formation, the three dimeric compounds, jozimine A~2~ (**3a**), ealapasamine C (**8**), and dimer **9**, that had been shown to have sub-micromolar activity against both early- and late-stage gametocytes, were assessed in the EIA. For this analysis we additionally included dioncophylline C (**2a**) as the most potent gametocytocidal monomeric NIQ (highly active against both early- and late-stage gametocytes) and the simplified synthetic analogue **22,** to examine if their observed moderate potency against gametocytes could be due to compromised functional viability of mature male gametocytes. Encouragingly, all five compounds, **2a**, **3a**, **8**, **9**, and **22** (at 2 μM), inhibited male gamete formation at more than 70%, with jozimine A~2~ (**3a**) being the most active one, completely compromising male gametogenesis ([Fig. 4](#fig4){ref-type="fig"}b). Taken together, our data point to dimeric compounds being multistage active targeting asexual parasites, gametocytes, and male gametes. On the other hand, the simplified analogues were selective towards asexual parasites and male gametes, with moderate activity against gametocytes.

3.4. Solubility and microsomal stability {#sec3.4}
----------------------------------------

For solubility and microsomal stability assays we prioritised dioncophylline C (**2a**) as the front runner compound based on its potency against asexual parasites, both drug-sensitive and resistant strains, and gamete activity. To investigate if stereochemical features have an influence on either solubility or microsomal stability of this class of compounds, we included its atropisomer **2b** for comparison of its data to that of its parent compound, dioncophylline C (**2a**). Additionally, to obtain a generalised overview on the solubility and microsomal stability of NIQs and their synthetic analogues, we selected a batch comprising a monomeric NIQ, dioncopeltine A (**5**), a dimer, compound **9**, and a synthetic analogue, compound **12**, thus, a top representative of each subclass. All compounds selected demonstrated good kinetic solubility in PBS at pH 6.5 ([Table 2](#tbl2){ref-type="table"}). Moreover, the five tested compounds, **2a**, **2b**, **5**, **9**, and **12**, showed divergent stabilities towards different microsomes. Dioncophylline C (**2a**) and the michellamine-type dimer **9** displayed good microsomal stability when incubated with human, mouse, or rat microsomes, as observed by minimal clearance of the parent compounds. The atropo-diastereomer **2b** of dioncophylline C (**2a**) and the structurally simplified analogue **12** displayed poor stability on exposure to rat and mouse microsomes with high rates of *in vitro* intrinsic clearance, while **5** was unstable only against mouse microsomes ([Table 2](#tbl2){ref-type="table"}).Table 2Solubility and microsomal stability of NIQs and their analogues.Table 2CompoundSolubility% Remaining after 30 minMicrosomal clearance (μl/min/mg)PBS (pH 6.5)HumanMouseRatHumanMouseRatReserpine[a](#tbl2fna){ref-type="table-fn"}\<5------------Hydrocortisone[a](#tbl2fna){ref-type="table-fn"}190------------Midazolam[a](#tbl2fna){ref-type="table-fn"}--\<7\<7\<7\>250\>250\>250Propranolol[a](#tbl2fna){ref-type="table-fn"}--6332\<739.693.9\>250MMV390048[a](#tbl2fna){ref-type="table-fn"}--92\>9997\<11.6\<11.6\<11.6Dioncophylline C (**2a**)170949595\<11.6\<11.6\<11.6Dioncopeltine A (**5**)20098\<7\>99\<11.6\>250\<11.6Atropisomer **2b**18083323615.495.186.6Synthetic dimer **9**200989996\<11.6\<11.6\<11.6Simplified analogue **12**18071\<7\<728.2\>250\>250[^9]

4. Discussion {#sec4}
=============

In this paper, we provide a first report on the multistage potency of NIQs and their synthetic analogues against intra-erythrocytic asexual and sexual stage *P. falciparum* parasites *in vitro*. Their activity profile fundamentally marks this class of compounds as chemical scaffolds with potential for the development of multistage-active antimalarial drugs that could emerge as a potent tool in the endeavour to eliminate malaria. Currently, no available antimalarial drug has this activity profile, since most such agents primarily target intra-erythrocytic asexual *P. falciparum* parasites ([@bib14]). Our data show stage-specific sensitivity to the compounds examined in the study with asexual-stage *Plasmodium* parasites being the most potently affected. The structurally unique dimeric NIQs, particularly jozimine A~2~ (**3a**), were pharmacologically efficient being highly active across all three distinct stages examined in the study. However, undesirable physicochemical properties, including high molecular weight (\>500 g/mol) and clogP (ranging between 7.36 and 7.45), could potentially limit their progress to become lead antimalarial candidates. On the other hand, the monomeric NIQs and simplified analogues were distinctively selective towards asexual parasites and male gametes with two compounds, dioncophylline C (**2a**) and **22**, emerging as validated multistage-active (TCP-1 and TCP-5) hits.

Five compounds, **2a**, **3a**, **8**, **9**, and **22**, displayed notable activity in blocking exflagellation of male gametes *in vitro*. This is the first report detailing the biological profile of this chemotype, making exploration of NIQs and their analogues, as a starting point for the development of gametocidal drugs for consideration as TCP-5 candidates, a rewarding goal. As the EIA correlates well with the standard membrane feeding assay ([@bib13]), which is the gold standard assay for confirmation of transmission blocking of drugs, these results further enhance the credentials of NIQs and their simplified analogues as transmission-blocking agents. It was surprising to note that natural dioncophylline C (**2a**) and the unnatural naphthyldihydroisoquinoline **22** both inhibited male gamete exflagellation, while demonstrating moderate gametocytocidal activity. However, this stage-specific profile is not new with the antifolates pyrimethamine and cycloguanil, which are known to have a similar activity profile ([@bib34]). In the case of dioncophylline C (**2a**) and the simplified analogue **22**, inhibition of exflagellation may be explained by these compounds either having a sterilising or a contraceptive effect on mature gametocytes resulting in their compromised functional viability, which has been described for other compounds earlier ([@bib34]). While the dimeric NIQs jozimine A~2~ (**3a**), ealapasamine C (**8**), and the michellamine-type dimer **9** were the most potent agents against gametocytes, these compounds were even 2.4 to 14-fold more active against intra-erythrocytic asexual stages of *P. falciparum*, demonstrating selectivity towards the aforementioned proliferative parasite stages.

The divergent stage-specific profiles of structurally related compounds investigated in this study raised pertinent questions from a drug-target perspective concerning the putative mode of action (MoA) of the most promising monomeric agent, dioncophylline C (**2a**). While our data strongly point to an inhibition of haemozoin formation as a possible MoA of this compound, given the β-haematin inhibition assay results, further investigations still need to confirm this activity intracellularly. Given the activity of this compound against male gametes (stages of the parasites devoid of the haem degradation biological process), our data hint at an inhibition of haemozoin formation as being only partly contributing to the overall MoA of dioncophylline C (**2a**). On the other hand, it is remarkable that dioncopeltine A (**5**), which had a resistance profile similar to that of chloroquine, did not inhibit β-haematin formation, suggesting possible different targets for this compound within the parasite. Indeed, since habropetaline A (**4**), although structurally closely related to dioncopeltine A (**5**), is more active to chloroquine-resistant parasites, it would be interesting to test its activity in the β-haematin assay as well. If it also lacked activity similar to dioncopeltine A (**5**), it would point to a different MoA of these compounds and that the chloroquine-resistance profile for dioncopeltine A (**5**) is not linked.

Although the antiplasmodial activity of NIQs had been demonstrated previously, from our data the activities of the most notable compounds investigated including dioncophylline C (**2a**), habropetaline A (**4**), dioncopeltine A (**5**), as well as the simplified analogues **22**, **23**, and **27**, matched quite well those obtained in previous studies ([@bib5], [@bib4], [@bib2], [@bib7]; [@bib17], [@bib21], [@bib20], [@bib22]; [@bib27]; [@bib36]). A major discrepancy (ca. 100-fold difference in the observed IC~50~ values) was noted for the dimeric alkaloid jozimine A~2~ (**3a**). Interestingly, the activity of ealapasamine C (**8**) against the NF54 strain was consistent to that from an earlier investigation ([@bib36]), while strikingly a 22-fold difference in the IC~50~ values measured against the K1 strain was observed. These variances could be attributed to differences in assay readouts and strains used in the respective studies.

Although bearing the typical functional groups of their highly potent NIQ parent compounds, generally most of the simplified analogues were less potent. Only a handful of them showed marked activity with IC~50~ \<1 μM against asexual *Plasmodium* parasites, with the achiral derivatives emerging as the most active. However, a most encouraging activity profile of the simplified analogues was their low-to-no cross resistance against multidrug-resistant strains, suggesting a different MoA, with minimal to no cytotoxicity observed against cells of the mammalian cell line. Furthermore, just like the monomeric NIQs, the simplified analogues have a predicted lipophilicity of \>4.2, which compares fairly well to that of preclinical and clinical antimalarial candidates (average value of 4.0) currently in development. This, in theory, implied that the compounds meet the new target product profiles of desired antimalarial drugs with particular reference to long half-life times ([@bib10]). A high lipophilicity provides the option of having long half-lives, enabling them to be used in a single-dose regimen ([@bib10]).

It is quite striking to note the impact of axial chirality on the microsomal stability differences between dioncophylline C (**2a**) and its metabolically less stable (*M*)-configured synthetic atropo-diastereomer, compound **2b**. This finding is in agreement with previous investigation where atropisomers were shown to have varied metabolic stability ([@bib24]; [@bib39]), although also contrary results have likewise been observed ([@bib39]). In a similar way, atropo-diastereomeric NIQ alkaloids had previously shown substantially different antiplasmodial activities ([@bib7]; [@bib16]).

5. Conclusion {#sec5}
=============

In the present study, NIQs have been - for the first time - validated as hit antiplasmodial compounds with *in vitro* activity against both early- and late-stage gametocytes of *P. falciparum* while also blocking exflagellation of male gametes. This is a significant finding as it implies that these compounds are active across all stages of the malaria parasite found in the human host, marking them as potential multistage-active antimalarial agents. In view of the goal of malaria elimination, this class of compounds could certainly play a vital role and as such deserves more attention. Among the investigated compounds, dioncophylline C (**2a**) was the most promising candidate for further exploration, as it consistently maintained good activity across all stages while also demonstrating good solubility and metabolic stability.
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